These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38720450)

  • 21. Screening and risk of hepatocellular carcinoma in patients with advanced fibrosis after hepatitis C virus eradication.
    Espina Cadena S; Casas Deza D; Julián Gomara B; Borao Laguna CV; Sierra Gabarda O; Lamuela Calvo LJ; Lorente S; Serrano T; Arbonés Mainar JM; Bernal Monterde V
    Rev Esp Enferm Dig; 2024 Jun; 116(6):305-311. PubMed ID: 38214165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.
    Shirai K; Hikita H; Sakamori R; Doi A; Tahata Y; Sakane S; Kamada Y; Murai K; Nishio A; Yamada R; Kodama T; Nozaki Y; Kakita N; Ishida H; Nakanishi F; Morishita N; Imanaka K; Sakakibara M; Tatsumi T; Miyoshi E; Takehara T
    PLoS One; 2022; 17(12):e0279416. PubMed ID: 36542633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.
    Toyoda H; Kanneganti M; Melendez-Torres J; Parikh ND; Jalal PK; Piñero F; Mendizabal M; Ridruejo E; Cheinquer H; Casadei-Gardini A; Weinmann A; Peck-Radosavljevic M; Dufour JF; Radu P; Shiha G; Soliman R; Sarin SK; Kumar M; Wang JH; Tangkijvanich P; Sukeepaisarnjaroen W; Atsukawa M; Uojima H; Nozaki A; Nakamuta M; Takaguchi K; Hiraoka A; Abe H; Matsuura K; Watanabe T; Shimada N; Tsuji K; Ishikawa T; Mikami S; Itobayashi E; Singal AG; Johnson PJ
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):72-80.e4. PubMed ID: 37442316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
    Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
    Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
    Azzi J; Dorival C; Cagnot C; Fontaine H; Lusivika-Nzinga C; Leroy V; De Ledinghen V; Tran A; Zoulim F; Alric L; Gournay J; Bronowicki JP; Decaens T; Riachi G; Mikhail N; Soliman R; Shiha G; Pol S; Carrat F; Ganne-Carrié N;
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101923. PubMed ID: 35405354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
    Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
    J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
    J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?
    Ahumada A; Rayón L; Usón C; Bañares R; Alonso Lopez S
    World J Gastroenterol; 2021 Oct; 27(40):6737-6749. PubMed ID: 34790004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
    Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M;
    Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
    Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
    Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
    Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
    World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response.
    Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
    J Chin Med Assoc; 2023 Sep; 86(9):795-805. PubMed ID: 37466658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
    Tabu K; Mawatari S; Oda K; Kumagai K; Inada Y; Uto H; Saisyoji A; Hiramine Y; Hashiguchi M; Tamai T; Hori T; Fujisaki K; Imanaka D; Kure T; Taniyama O; Toyodome A; Ijuin S; Sakae H; Sakurai K; Moriuchi A; Kanmura S; Ido A
    PLoS One; 2020; 15(8):e0237475. PubMed ID: 32790728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response.
    Toyoda H; Tada T; Yasuda S; Mizuno K; Ito T; Kumada T
    Clin Infect Dis; 2020 Mar; 70(6):1208-1214. PubMed ID: 31056696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals.
    Shiha G; Waked I; Soliman R; Elbasiony M; Gomaa A; Mikhail NNH; Eslam M
    Liver Int; 2020 Nov; 40(11):2828-2833. PubMed ID: 32946647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
    Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
    J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus.
    Kuo YH; Kee KM; Hung CH; Lu SN; Hu TH; Chen CH; Wang JH
    Kaohsiung J Med Sci; 2022 Mar; 38(3):268-276. PubMed ID: 34687140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    Mueller PP; Chen Q; Ayer T; Nemutlu GS; Hajjar A; Bethea ED; Peters MLB; Lee BP; Janjua NZ; Kanwal F; Chhatwal J
    J Hepatol; 2022 Jul; 77(1):55-62. PubMed ID: 35157959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.